[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345057-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345057-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","efficacy-and-mechanisms-of-cdk46-inhibitors-in-breast-cancer-review","Efficacy and Mechanisms of CDK4/6 Inhibitors in Breast Cancer - Review","","Breast cancer remains a leading cause of cancer-related mortality among women worldwide, making therapeutic breakthroughs essential. Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that function by blocking CDK4/6 activity, halting cell-cycle progression and promoting apoptosis in hormone receptor-positive, HER2-negative/positive subtypes. In combination with endocrine medicines such as letrozole and fulvestrant, clinical trials show improved progression-free survival. Resistance mechanisms and common toxicities, including fatigue, gastrointestinal disturbances, and neutropenia, still require active management. Emerging next-generation strategies, adaptive trials, and novel biomarkers support more personalized approaches beyond breast cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/efficacy-and-mechanisms-of-cdk46-inhibitors-in-breast-cancer-review/345057/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/efficacy-and-mechanisms-of-cdk46-inhibitors-in-breast-cancer-review/345057.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How do CDK4/6 inhibitors act in breast cancer cells?","Question",{"text":63,"@type":64},"They inhibit CDK4/6 activity, disrupting cell-cycle regulation, leading to cell-cycle arrest and promoting apoptosis. This mechanism underpins their targeted therapeutic effect.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the benefit of combining CDK4/6 inhibitors with endocrine medicines?",{"text":68,"@type":64},"Combining them with endocrine treatments such as letrozole and fulvestrant improves clinical outcomes, including progression-free survival in clinical trials. Some cases also show complete survival.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is resistance still a major issue and how is it addressed?",{"text":72,"@type":64},"Resistance mechanisms are identified as primary acquired problems despite effectiveness. The document emphasizes combined approaches with additional targeted medicines and ongoing investigation of new therapeutic plans.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345057,1790158918,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Tech Science Press  \n| Doi:10.32604/or.2026.073601\u003Cbr>REVIEW | \u003Cbr>|\n| --- | --- |\n| E􀂛cacy and Mechanisms ofCDK4/6 Inhibitors in Breast Cancer: Advancing Targeted 􀀗erapeutic Strategies\u003Cbr>Mohsina Patwekar1,2, Faheem Patwekar3, Zulhisyam Abdul Kari1,4, *,\u003Cbr>Muhammad Rajaei Ahmad Mohd Zain5, *, Arifullah Mohammed6 and Rohit Sharma7, *\u003Cbr>1 Department of Agriculture Science, Faculty of Agro-Based Industry, Universiti Malaysia Kelantan, Jeli, Kelantan, Malaysia 2 Department of Pharmacology, Luqman College of Pharmacy, PB 86, Old Jewargi Road, Gulbarga, Karnataka, India 3 Department of Pharmacognosy, Luqman College of Pharmacy, PB 86, Old Jewargi Road, Gulbarga, Karnataka, India 4 Advanced Livestock and Aquaculture Research Group, Faculty of Agro-Based Industry, Universiti Malaysia Kelantan, Jeli Campus, Jeli, Malaysia\u003Cbr>5 Department of Orthopaedics, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia 6 Department of Biotechnology, Koneru Lakshmaiah University (KLEF), Vaddeswaram Campus, Guntur, Andhra Pradesh, India 7 Department of Rasa Shastra and Bhaishajya Kalpana, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India\u003Cbr>*Corresponding Authors: Zulhisyam Abdul Kari. Email: [zulhisyam.a@umk.edu.my](zulhisyam.a@umk.edu.my);\u003Cbr>Muhammad Rajaei Ahmad Mohd Zain. Email: [rajaei@usm.my](rajaei@usm.my); Rohit Sharma. Email: [rohitsharma@bhu.ac.in](rohitsharma@bhu.ac.in)\u003Cbr>[Received: 22 September 2025](Received: 22 September 2025); [Accepted: 29 December 2025](Accepted: 29 December 2025); [Published: 23 March 2026](Published: 23 March 2026)\u003Cbr>ABSTRACT: Breast cancer remains the primary cause of cancer-related mortality for women globally; therefore, further breakthroughs in treatment approaches are crucial. Palbociclib, ribociclib, and abemaciclib are among the Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors that have become an innovative family of targeted therapy for hormone receptor-positive, Human Epidermal Growth factor receptor 2 (HR􀀔/HER2􀀐) breast cancer. 􀀗ese inhibitors work by preventing the action of CDK4/6, which are crucial in the regulation of the cell cycle. Leading cancer cells to cell cycle arrest and undergo apoptosis. When these inhibitors are used with endocrine medicines like letrozole and fulvestrant, clinical trials lead positive impact in progression-free survival and, in a few cases, complete survival. However, despite their e􀂚ectiveness, resistance mechanisms are primary and current acquired problems, requiring combined approaches with additional targeted medicines and continuous investigation into innovative therapeutic plans. To maintain patient compliance and quality of life, common side e􀂚ects such as tiredness, gastrointestinal problems, and neutropenia need to be e􀂚ectively managed. 􀀗ere is hopefulness for wider oncological applications as next-generation CDK inhibitor development and adaptive clinical trials continue to test their potential beyond breast cancer. CDK4/6 inhibitors continue to be a key part of breast cancer treatment as cancer biology advances, marking a major advancement towards more potent and customized cancer medicines. 􀀗is review aims to provide current evidence on CDK4/6 inhibitors in HR􀀔/HER2􀀐 breast cancer, highlighting their mechanisms, interaction with endocrine resistance, combination strategies, and emerging biomarkers guiding personalized therapy.\u003Cbr>KEYWORDS: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors; breast cancer; targeted therapy; endocrine therapy; resistance mechanisms; combination treatments |  |\n\n1 Introduction  \nBreast cancer is the most common cancer in women across the globe to receive a diagnosis, which continues to be the main cause of mortality from cancer. 􀀗e WHO (World Health Organization) predicts  \nCopyright © 2026 􀀗e Authors. Published by Tech Science Press.  \n􀀗is work is licensed under a Creative Commons Attribution 4.0 International License, which perm","cbCais86SAvnFF7l","https://ap.wps.com/l/cbCais86SAvnFF7l","pdf",1490268,25,"English","# Introduction\n# Efficacy and mechanisms of CDK4/6 inhibitors\n## Cell-cycle regulation and apoptosis\n## Clinical impact with endocrine therapy\n# Resistance mechanisms and combination strategies\n## Managing adverse effects\n# Emerging biomarkers and future directions","[{\"question\":\"How do CDK4/6 inhibitors act in breast cancer cells?\",\"answer\":\"They inhibit CDK4/6 activity, disrupting cell-cycle regulation, leading to cell-cycle arrest and promoting apoptosis. This mechanism underpins their targeted therapeutic effect.\"},{\"question\":\"What is the benefit of combining CDK4/6 inhibitors with endocrine medicines?\",\"answer\":\"Combining them with endocrine treatments such as letrozole and fulvestrant improves clinical outcomes, including progression-free survival in clinical trials. Some cases also show complete survival.\"},{\"question\":\"Why is resistance still a major issue and how is it addressed?\",\"answer\":\"Resistance mechanisms are identified as primary acquired problems despite effectiveness. The document emphasizes combined approaches with additional targeted medicines and ongoing investigation of new therapeutic plans.\"}]","Efficacy and Mechanisms of CDK4/6 Inhibitors in Breast Cancer - Review | PDF",1790056380,63,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0bba7541dd0a3d4e3f93b4588192c5a.webp",983,1271,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6c71956fdd37e0fa8b6a39cb292481c.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b2a41bf1b48b90c9306d0e6a0827995.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ac4f97b4814c79d022bd8ffee5c2954.webp",980,1267]